Use access key #2 to skip to page content.
$0.23 0.01 (4.40%)
1/9/2009 3:59 PM

ENTREMED, INC. (ENMD)

CAPS Rating:
*

A clinical-stage pharmaceutical company focused on developing multi-mechanism oncology drugs that target disease cells directly and the blood vessels that nourish them.

View All Commentary (ENMD)

Recs

0

Avatar jilbear (45.27) Submitted: 4/15/07 10:50 AM : Underperform Start Price: $1.78 ENMD Score: 48.99

This company can only go down from the information available. They are eating cash. This is coming off their second stock offering. It will be years until any of their medications ever hit the market. The bottom line is, this company wont be profitable for at least another 3 years, and I dont think it can stick it out without exhausting its cash supply.

Report this Post Replies: 0 | Reply | Permalink

Featured Broker Partners

Sponsored Links